Advertisement
The Leading Source for Pharmaceutical & Biopharmaceutical Manufacturing News
Subscribe to Pharmaceutical Processing
View Sample

FREE Daily Email Newsletter

Industry Presses FDA to Allow More Online Ads

November 11, 2009 10:12 am | News | Comments

MATTHEW PERRONE AP Business Writer WASHINGTON (AP) — As federal regulators take their first tentative steps toward policing the wild west of medical information online, pharmaceutical companies are pressing their case to market drugs via Google, Twitter and other Web sites.

TOPICS:

Pfizer Job Cuts Could Cost Company Tax Incentives

November 11, 2009 4:29 am | News | Comments

ST. LOUIS (AP) — Now that the drug maker Pfizer has announced plans to cut 600 jobs in Chesterfield, St. Louis County officials are rethinking $7 million in tax breaks promised to the company over the next decade.

TOPICS:

Teva Gets FDA Approval for Generic Prevacid

November 11, 2009 3:44 am | News | Comments

NEW YORK (AP) — Teva Pharmaceutical Industries Ltd. said Tuesday the Food and Drug Administration approved its generic version of the heartburn drug Prevacid. Teva will sell 15-milligram and 30-milligram delayed-release capsule versions of the drug.

TOPICS:
Advertisement

FDA Licenses GSK's H1N1 Vaccine, Last of the Five US Suppliers to be Approved

November 11, 2009 3:41 am | News | Comments

The FDA has finally approved GlaxoSmithKline's H1N1 vaccine. GSK is the last of five manufacturers supplying vaccine to the United States to receive approval for its pandemic product.

TOPICS:

FDA Approves Roxane Labs ANDA for Perindopril Erbumine Tablets

November 11, 2009 3:39 am | News | Comments

Roxane Laboratories, Inc.announced today the approval of its Abbreviated New Drug Application (ANDA)for Perindopril Erbumine Tablets, 2mg, 4mg and 8mg by the U.S. Food and DrugAdministration. The product is available in bottles of 100 for immediateshipment to wholesalers and pharmacies nationwide.

TOPICS:

Bristol-Myers Signs Development Deal with Alder

November 11, 2009 3:36 am | News | Comments

NEW YORK (AP) — Bristol-Myers Squibb Co. and Alder Biopharmaceuticals Inc. said Tuesday they signed a collaboration deal potentially worth $1 billion, with a key focus on a rheumatoid arthritis treatment.

TOPICS:

Nucryst to Sell Operations and Assets to Smith & Nephew, Merge with Westaim

November 11, 2009 3:32 am | News | Comments

TORONTO — Nucryst Pharmaceuticals Corp. said Tuesday it has signed a deal to sell its all of its operations and assets including its nanocrystalline silver technology and merge the company with its majority shareholder.

TOPICS:

Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration

November 11, 2009 3:26 am | News | Comments

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. have entered into agreements to expand and extend their existing global collaboration to discover, develop, and commercialize fully-human therapeutic monoclonal antibodies.

Advertisement

Mylan Receives FDA Approval for Generic Version of Prevacid Through its Subsidiary Matrix Laboratories

November 11, 2009 3:23 am | News | Comments

Mylan Inc. has announced that its privately held Indian subsidiary, Matrix Laboratories Limited, has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Lansoprazole Delayed-release (DR) Capsules, 15 mg and 30 mg.

TOPICS:

Time for a Change in Pharmaceutical Process Cooling?New Technology Can Greatly Reduce Water, Energy Use

November 10, 2009 5:51 am | Articles | Comments

Recent regulatory rumblings suggest it may be time for pharmaceutical processors to take a closer look at their use of water resources. Two federal studies released in 2009 reflect increasing scrutiny of the impact manufacturers including drug companies have on the water supply.

TOPICS:

Status of Pfizer and Wyeth Research Facilities

November 10, 2009 4:05 am | News | Comments

The Associated Press Pfizer Inc., which just acquired fellow drugmaker Wyeth, is closing six of the two companies' research sites and keeping open 14 others. Two Cambridge, Mass., sites will operate as one.

TOPICS:

Teva Wants to Expand Copaxone Patent Lawsuit

November 10, 2009 4:00 am | News | Comments

NEW YORK (AP) — Teva Pharmaceutical Industries Ltd. said Tuesday it plans to expand a suit against Momenta Pharmaceuticals Inc. and Sandoz Inc., which are hoping to market a generic version of Teva's multiple sclerosis drug Copaxone.

TOPICS:

Ironwood and Astellas Announce Japan Licensing Agreement for Linaclotide

November 10, 2009 3:48 am | News | Comments

Ironwood Pharmaceuticals, Inc. and Astellas Pharma Inc. today announced that they have entered into an agreement providing Astellas exclusive rights to develop and commercialize the investigational compound linaclotide in Japan, Indonesia, Korea, the Philippines, Taiwan, and Thailand.

TOPICS:

Cerimon Pharmaceuticals Acquires European Rights to its Topical Diclofenac Sodium Patch

November 10, 2009 3:36 am | News | Comments

Cerimon Pharmaceuticals, Inc., announced today that it has acquired exclusive rights to develop and commercialize its once-daily topical diclofenac sodium patch in Europe, including most countries in the European Union, Turkey, Switzerland, Norway, the Balkan countries and Iceland.

TOPICS:

FDA Approves Drug Treatment for Rare Cancer

November 10, 2009 3:33 am | News | Comments

The FDA has approved Istodax (romidepsin), an injectable medication, for treatment of patients with a rare form of cancer known as Cutaneous T-cell Lymphoma (CTCL). Cutaneous T-cell lymphoma is a slow-growing cancer of infection-fighting white blood cells called T-lymphocytes.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading